|
|||||
|
|
Impact of MammaPrint on Clinical Decision‐Making in South African Patients with Early‐Stage Breast Cancer |
|
| Authors: | Heinrich Pohl MB ChB MMed Maritha J. Kotze PhD Kathleen A. Grant PhD Lize van der Merwe MSc PhD Fredrieka M. Pienaar MB ChB MMed Ettienne J. Myburgh MB ChB FCS MMed |
| Affiliation: | 1. Department of Surgery, University of Stellenbosch, Tygerberg, South Africa;2. Division of Anatomical Pathology, Department of Pathology, Faculty of Medicine and Health Sciences, University of Stellenbosch, Tygerberg, South Africa;3. Department of Biomedical Sciences, Faculty of Health and Wellness, Cape Peninsula University of Technology, Bellville, South Africa;4. Division of Molecular Biology and Human Genetics, Faculty of Medicine and Health Sciences, University of Stellenbosch, Tygerberg, South Africa;5. Department of Statistics, University of the Western Cape, Bellville, South Africa;6. GVI Oncology, Mediclinic Panorama, Cape Town, South Africa;7. Private Practice, Mediclinic Panorama, Cape Town, South Africa |
| Abstract: | The aim of the study was to evaluate the impact of MammaPrint on treatment decision‐making in patients with breast cancer. Clinicopathologic information of all breast cancer patients referred for MammaPrint testing in South Africa was collected from 2007 until 2014. A total of 107 patients (109 tumors) with estrogen receptor/progesterone receptor positive and human epidermal growth factor receptor‐2 negative tumors were selected with tumors ≥10 mm, or when 1–3 nodes were involved without extra‐nodal extension. None of the clinical indicators correlated significantly with the MammaPrint risk classification, which changed the decision for adjuvant chemotherapy in 52% of patients. Of 60 patients who were clinically high risk, 62% had a low‐risk MammaPrint result and of the 47 clinically low ‐risk patients 40% had a high‐risk MammaPrint result. This study indicates that MammaPrint could reduce the need for adjuvant chemotherapy by 17% using the selection criteria stipulated. The significant impact on treatment decisions confirmed the clinical utility of MammaPrint independent of standard clinicopathologic risk factors as supported by long‐term clinical outcome studies. |
| Keywords: | adjuvant chemotherapy breast cancer genomic profiling impact Mammaprint |